The Analytical Scientist / Issues / 2026 / March / The Oral GLP1 Era Has Arrived
Pharma and Biopharma Liquid Chromatography Opinion & Personal Narratives

The Oral GLP‑1 Era Has Arrived 

And chromatographers are about to be very busy…

By Sean Orlowicz 03/12/2026 3 min read

Share

Objective:

Enhance emphasis on the significance of the FDA's approval.

Key Findings:
  • Include specific examples or data to support claims.
Interpretation:

Elaborate on implications for future drug development.

Limitations:
  • Suggest potential solutions for the challenges identified.
Conclusion:

Reiterate the urgency of adapting analytical strategies.

About the Author(s)

Sean Orlowicz

Principal Market Development Manager – Pharmaceutical, Phenomenex

More Articles by Sean Orlowicz

Recommended

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment